




































The potential link between aging and insulin/IGF-1 
signaling has attracted substantial attention during last 
years. This connection was evidenced by an increase in 
incidence of insulin resistance and type 2 diabetes in 
accelerated aging syndromes in humans, on the one 
hand, as well as by life span extension due to caloric 
restriction (CR) in rodents, on the other hand. 
Concomitant reduction in plasma insulin and plasma 
glucose levels, which implies increased sensitivity to 
insulin, emerges as a hallmark of increased longevity 
[1]. Hyperglycemia is an important aging factor 
involved in generation of advanced glycosylation end 
products (AGEs) [2]. There is evidence that 
hyperinsulinemia favors accumulation of oxidized 
proteins   [2]. Untreated diabetics with elevated glucose 






































such as impaired wound healing, obesity, cataracts, 
vascular and microvascular damage [3]. It is important 
to stress that hyperinsulinemia is a significant factor not 
only in aging but also in the development of cancer [3-
5]. 
 
The concept of CR mimetics is now being intensively 
explored [6,7]. CR mimetics involve interventions that 
produce physiological and anti-aging effects similar to 
CR. It was suggested to use antidiabetic biguanides as a 
potential anti-aging treatment [3,10-14]. The 
antidiabetic drugs, phenformin and buformin, were 
observed to reduce hyperglycemia and produce the 
following effects: improved glucose utilization, reduced 
free fatty acid utilization, gluconeogenesis, serum 
lipids, insulin and IGF-1, and reduced body weight both 
in humans (including cancer patients) and experimental 
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metformin [11,17-21]. Of note, in all experiments 
related to the study of potential geroprotective action 
the treatment with metformin was started at the young 
age. In the same time, the possibility of a successful 
treatment with geroprotectors started at the middle or 
old age is very appealing [22]. There are data which 
ascribe some distinctions effects in regard of the caloric 
restriction or other geroprotective agents depending on 
the stage of ontogenesis when the exposure has been 
started and to the duration of the latter [22,23].  
In this paper we present the results of treatments with the 



























Age-related body weight dynamics 
 
The body weight of mice in both control and 
metformin-treated groups increased with age, exceeding 
by 16 months the body weight of 3-month-old animals 
by 34.31%. There was no difference in the mean body 
weight of mice exposed and non-exposed to the drug 
until the age of 20 months, and a tendency to a decrease 
of the body weight was observed in metformin treated 
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The amount of food consumed daily by mice during the 
period of observation was similar in the control group 
and in metformin-treated groups (Fig. 1B). The amount 
of water consumed by mice varied during the period of 
observation and was practically the same in all groups 
(data are not shown). 
 
Age-related dynamics of estrous function in mice 
 
The length of estrous cycles in the control female SHR 
mice was not significantly changed with age, whereas it 
was significantly decreased at various  age in mice 
exposed to metformin  from the age of 3, 9 or 15 months 
in comparison with the estrous cycle status in  controls of 







































irregular estrous cycles increased with  age in the control 
mice but not in mice treated with metformin until the age 
of 15 months  (Table 1, Fig. 1D), independently on the  
time of the start of metformin treatment.  
 
Age-related dynamics of body temperature in mice 
 
There was no significant age-related changes in average 
body temperature in the control  mice. Treatment with 
metformin started at the age of 3 months decreased 
body temperature at the age of 15 months as compared 
with age-matched controls. Also, body temperature was 
decreased between the 11th and 18th months of life in 
mice treated with the drug from the age 9 months. 
Metformin administration started at the age of 15 
months failed influence the average body temperature in 























































< 5 days  5-7 days  > 7 days 
Control 
3   30  6.9 ± 0.28  0  64  36  81 
7   29  8.1 ± 0.46  0  44  56  56 
11  36  7.5 ± 0.50  0  44  56  50 
14-15   24  7.4 ± 0.56  0  71  29  29 
18  23  8.1 ± 0.56  0  33  67  39 
21  21  8.0 ± 0.49  0  25  75  19  
Metformin, 3 months 
3   33  7.1 ± 0.26  0  64  36  92 
7   32  6.5 ± 0.24 **  3  74 *  23 *  92,5 *** 
11  30  6.2 ± 0.31 *  27  50  23 *  84 ** 
14-15   24  6.4 ± 0.34  3,7  81,5  14,8  87 ** 
18  20  7.7 ± 0.52  0  40  60  50 
21  14  6.5 ± 0.37 *  0  75  25  43 
Metformin, 9 months
11  32  6.1 ± 0.30 *  22  56  22 *  80 ** 
14-15  29  6.6 ± 0.32  7  76  17  81** 
18  22  7.7 ± 0.41  0  50  50  50 
21  12  7.7 ± 1.37  0  67  33  25 
Metformin, 15 months
18   19  7.6 ± 0.37  0  50  50  42 
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parameters in mice 
 
Treatment with metformin started at the age of 3, 9 or 
15 months failed influence levels of glucose, total 
cholesterol, triglycerides, and insulin in the serum 
estimated when mice were 16.5 month old (Table 2).  
 
Survival and longevity of female SHR mice 
 
Treatment with metformin started at the age of 3 
months shifted to the right the survival curve as 
compared with the controls (Fig. 2A). The effect of the 










































sed (Fig. 2C) and it was absent in the group with 
metformin started at oldest age (Fig. 2E). According to 
the log-rank test  the difference in survival of female 
SHR mice subjected to metformin treatment from the 
age of 3, 9 or 15 months, compared to the age-matched 
control groups, is insignificant (p-value is 0.181; 0.97 
and 0.478, correspondingly). According to the estimated 
parameters of the Cox’s regression, metformin 
treatment started at the age of 3 months decreased the 
relative risk of death compared to the control group (β = 
-0.227; exp (β = 0.797; se (β)= 0.169; p  = 0.173). 
Metformin treatment started at the age of 9 or 15 
months produced no effect on the relative risk of death 

















































































The differences in survival were reflected in parameters 
of longevity. Metformin treatment started at the age of 3 
or 9 months increased mean life span (+14.1% and 
6.1%, correspondingly, p>0.05), median by 17.5% and 
6.6%, correspondingly, but practically did not influence 
when started at the age of 15 months. Maximum life 
span was increased by 1 month only in mice treated 
from youngest age (Table 3). It is worthy to note that 
the mean life span of tumor-free mice has increased by 
20.7% in ‘the youngest age started’ group, by +7.1% in 
‘middle-age started’ group and was reduced by 12.8% 
in the ‘old age started’ group. Parameter α of the 
Gompertz model was higher by 1.4 times in the group 
subjected to metformin treatment from the age of 3 
months and by 1.9 times in the middle-age started group 
as compared with the controls (p < 0.05).  At the same 
time, it was slightly reduced in the old age started group 
treated with metformin. The difference between the 





































(Table 3).  
 
Development of spontaneous tumors in female SHR 
mice 
 
According to the long-rank test there were no significant 
differences in age-related distributions of the total tumors 
occurrence in control and metformin-treated groups (Fig. 
2). The first tumor-bearing mice (malignant lymphoma) 
died at the age of 246 days in the control group and at the 
300th day (+22%) in the group of mice treated with 
metformin starting at 3 mo, while at the 363rd day 
(+24.7%) in the group exposed to metformin starting 
from middle-age and at 482nd day (+5.2%) in the oldest 
metformin-treated group as compared to the age-matched 
controls (Table 4). The mean life spans of tumor-bearing 
mice were similar being increased by 7.9%, 7.3% and 
5.4% in groups treated with metformin from the age 3, 9 




Parameters Control-3  MF-3  Control-9  MF-9  Control-15  MF-15 
No. of mice at start of the 
treatment  
119 51  97  45  69  33 
Mean life span, days  511 ± 20.3  583 ± 26.7 
(+14.1%) 
583 ± 17.9 
 
619 ± 19.5 
(+6.2%) 
668 ± 15.7  647 ± 21.4 
Median, days  525  617  591  630  636  636 
Mean life span of last 10%, 
days 
881 ± 12.8  897 ± 27.8  892 ± 12.4  820 ± 14.1  913 ± 8.8  892 ± 47.0 
Maximum life span, days  941  972  941  855  941  966 
α x 10
3, days
























No. of tumor-free mice   62  25  45  15  29  16 
Mean life span of tumor-
free mice, days 
478 ± 32.7  577 ± 44.3 
(+20.7%) 
609 ± 29.7 
 
652 ± 31.5 
(+7.1%) 



















Control           -  7.3 ± 1.50  2.9 ± 1.06  1.5 ± 0.46   0.17 ± 0.12 
Metformin     3 months  8.1 ± 0.64  2.7 ± 0.37  1.0 ± 0.03    0.49 ± 0.47 
  9 months  7.9 ± 0.59  2.5 ± 0.27  0.9 ± 0.22    0.06 ± 0.05 
15 months  7.8 ± 0.78  2.6 ± 0.21  1.1 ± 0.08    0.19 ± 0.18 
   



































Total tumor incidence in “effective” control female 
mice (survived by the time of the death from the first 
tumor in the experiment) was practically the same in all 
metformin-treated and control groups (Table 4). 
Mammary carcinomas and leukaemia developed most 
frequently, in accord with oncologic characteristics of 
the female SHR mice [19]. Treatment with metformin 
failed to influence the total incidence of malignant 
tumors (Table 4).  There were no cases of lung 
adenocarcinomas in the mice treated with metformin 
from the age of 3 or 15 months whereas 3 cases of this 
malignancy were detected in the relevant controls. 
There was no significant difference in the incidence of 
any other tumors between mice treated with metformin 




We have found that long-term treatment with the 




































span of female SHR mice when initiated at the young 
and middle age but not at the old age. Taken together 
with our previous results [9,10,18-21,24], we conclude 
that treatment with metformin is most beneficial, in 
females, when started relatively early in life.  
  
Metformin slowed down disturbances in the estrous 
function of mice regardless of mice age. Thus, effects of 
metformin on estrous function can be partially 
dissociated from extension of lifespan and cancer 
prevention. Noteworthy, restoration of the hypothalamic 
sensitivity to estrogens with phenformin restored 
estrous cycles in 16-month-old female rats [25]. 
Importantly, metformin improves menstrual regularity, 
leading to spontaneous ovulation in women with 
polycystic ovary syndrome [26].  
 
Treatment with metformin did not affect body weight 
and food consumption as well as metabolic and 
hormonal parameters, while decreasing body 
   




Parameters Control-3  MF-3  Control-9  MF-9  Control-15  MF-15 
Effective number of mice
a 103  48  97  45  69  33 
Age of the death of the 1
st 
TBM 
246 300  291 363  458 482 
Number of TBM
b (%)  57 (55.3%)  26 (54.2%)  54 (55.7%)  30 (66.7%)  40 (58.0%)  17 (51.5%) 
Total number of tumors  60  26  57  31  43  18 
Number of tumors per TBM  1.05  1.00  1.06  1.03  1.08  1.06 
Number of malignant TBM 
(%) 
54 (49.5%)  26 (54.2%)  51 (52.6%)  27 (60.0%)  37 (53.6%)  16 (48.5%) 
Mean  life span of TBM, days  547 ± 22.2  590 ± 31.3 
(+7.9%) 
562 ± 21.5  603 ± 24.4 
(+7.3%) 
631 ± 18.9  665 ± 34.1 
(+5.4%) 
Localization and type of tumors 
Mammary  adenocarcinoma  42 (40.8%)  23 (47.9%)  40  (41.2%)  20 (44.4%)  27 (39.1%)  12 (36.4%) 
Leukemia/lymphoma  7 (6.8%)  2 (4.2%)  6 (6.2%)  3 (6.7%)  6 (8.7%)  3 (9.1%) 
Ovary:              hemangioma 
             granulesa-cell tumor      



















Liver:      holangiocarcinoma  2  -  2  -  2  - 
Lung:                      adenoma      













Skin:                     paplilloma 













Soft tissues:              sarcoma  -  -  -  -  -  1 
Utery:                hemangioma   -  -  -  1  -  - 
Spleen:               hemangioma  1  -  1  -  1  - 
 
a, number of mice  surviving the first tumor bearing animal death . 
b, TBM, tumor‐bearing mice. temperature, extending life span and delaying cancer. 
These data argue against the notion that metformin is a 
CR mimetic. It was also shown that metformin and CR 
had different metabolic effects [27-29].  
 
 Life span extension by CR may differ among species 
and depends on the age of onset. Thus, Lipman et al. 
[30] reported that CR does not extend life span of 
F344xBNF1 rats when initiated  in late middle age (18 
months) or in old age (26 months). They had reported 
similar findings for the Long-Evans rat strain [31]. In 
contrast, Dhabbi et al. [32] found that CR increases life 
span of B6C3F1 mice when initiated at 19 months of 
age.  In their turn, Weindruch and Walford [28] 
reported that CR initiated in 12-month-old mice 
significantly extended life span, but not as markedly as 
initiated at weaning.  Yu et al. [57] initiated CR in rats 
at the age of 6 weeks or 6 months. It was found that 
when CR was limited to the rapid growth period, it did 
not markedly increase the age of 10th percentile 
survivors. When CR was initiated after the rapid growth 
period, it was almost as effective in increasing the age 
of the 10th percentile survivors as CR initiated at 6 
weeks of age [33].  
 
Harrison et al. [34] and Miller et al. [35] studied effect 
of treatment with rapamycin started at the age of 9 or 20 
months.  The two data sets were not produced simul-
taneously, but they do represent work done using the 
same conditions of drug preparation, diet, water source, 
housing, and genetic stocks, with only a 1 year lag 
between start dates. For male mice, starting rapamycin 
at 9 months rather than at 20 months did not lead to any 
improvement in survival. For female mice, there was a 
suggestion that treatment started at the age of 9 months 
may lead to some slight decline in mortality risk before 
1000 days of age, but comprehensive statistical 
treatment of the results failed to reveal any significance 
in the differences [35].    
 
In our study, treatment with metformin did not affect 
total tumor incidence, but led to the increase in the 
mean life span of tumor-bearing mice. In contrast, the 
time of detection of the first tumor was mainly 
postponed in metformin-treated mice when such 
treatment has been initiated early and in the middle age.  
In transgenic HER-2/neu mice, the similar treatment 
with metformin did not change the incidence of 
mammary adenocarcinomas. However, it increased their 
latency and decreased multiplicity [18]. Antidiabetic 
biguanides phenformin and buformin inhibited 
spontaneous and chemically induced carcinogenesis in a 
number of experimental models [10,11]. Biguanides 
decreased breast carcinoma risk in diabetes mellitus 
type 2 [16,18, 36, 37].  
Markers of cellular senescence were studied in 
fibroblasts obtained from skin of 11-, 16-, 19- and 23-
months-old SHR mice treated with metformin since the 
3rd and 9th months of life [38]. Significant differences 
were observed between the average number of 
senescence-associated heterochromatic foci, the average 
of area nuclei and fluorescence intensity of nucleus after 
staining for γ-H2AX in control and metformin-treated 
animals. Also, it was shown that metformin prevented 
the accumulation of fibroblasts with large area of 
nuclei, high activity of senescence-associated β-
galactosidase, and high fluorescence intensity after 
staining for γ-H2AX. Noteworthy, γ-H2AX is also a 
marker of mTOR-dependent cellular senescence in the 
absence of DNA damage [39]. Rapamycin decreases 
levels of γ-H2AX in senescent cells [39]. Short-term 
dietary restriction reduces levels of γ-H2AX associated 
with cell senescence in mice [40]. Evidently, metformin 
delays the “old” cells accumulation and prolongs the 
organism youth. 
 
Discussing recently the late-life interventions, Flurkey 
et al. [22] noted that it is unlikely that most people will 
consider anti-aging treatments when they are young. At 
the same time, most of the available data show that 
treatments with various drugs started in younger rodents 
were more effective in life span extension as compared 
to these interventions started in late middle or old age 
[22,34,35,41,42]. Our data are not exception from this 
rule and suggest   “a program of aging” switching on at 
early age [3,8]. The realization of this program could 
depend on gender differences as it was shown in our 
experiments with metformin [21].   
 
 MATERIAL AND METHODS  
 
Animals. Outbred Swiss-derived female SHR mice 
were purchased from the “Rappolovo” Animal Farm of 
the Russian Academy of Medical Sciences. The mice 
were kept in groups of 5-7 animals in polypropylene 
cages (30 x 21 x 10 cm) under standard light/dark 
regimen (12 hours light:12 hours darkness) at 22 ± 2
oC,  
and received standard laboratory chow [43] and tap 
water ad libitum. 
 
Experimental design. Two hundred and eighty eight 
female SHR mice were under observations. One 
hundred and twenty nine mice were intact and served as 
a control. Other mice were treated with metformin (1, 1-
Dimethylbiguanide hydrochloride, Biomedicals, 
France) with drinking water (100 mg/kg of body 
weight) daily starting at the age of 3 months (61 mice), 
9 months (55 mice) and 15 months (43 mice).  The dose 
of metformin is similar to used in our earlier 
experiments with SHR, 129/Sv or HER-2/neu mice [10, 
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Recalculation for humans gives in average 510 mg/m
2, 
that are less than commonly used in clinical practice in 
diabetics (1.0 – 2.5 g per day). Once a week all mice 
were palpated for detection of mammary tumors 
appearance. The localization and the size of tumors 
were registered on the special charts. Once a month all 
mice were weighted and, simultaneously, the amount 
of daily consumed food (g) and water (ml) was 
measured, and their rates per mouse and per body 
weight unit were calculated. Every 3 months, vaginal 
smears of the animals were examined cytologically 
daily for 2 weeks to estimate the estrous function. In 
the same period, rectal body temperatures of the mice 
were measured with an electronic thermometer, TPEM 
(KMIZ, Russia). 
 
The time of appearance of mammary tumors was 
evaluated by palpation, and the neoplastic masses were 
measured with calipers in the two perpendicular 
diameters. Progressively growing masses of >3 mm in 
mean diameter were regarded as tumors. At the age of 
16.5 months 10 mice from each group were sacrificed 
by decapitation after overnight fasting. Samples of 
serum were obtained and stored at the -20
oC for 
subsequent metabolic and hormonal analyses. Other 
animals were observed until their natural deaths. The 
date of each death was registered, and the mean life 
span, median, the age at which 90% of the animals died, 
and the maximum life span were estimated. 
 
Metabolic and hormonal assays.   The serum levels of 
glucose were estimated by enzyme colorimetric 
(glucose-oxidase) method with kits from  “Impact” 
(Moscow, Russia); cholesterol and triglycerides - by 
enzyme colorimetric method with kits of  “Olvex” 
(St.Petersburg, Russia); insulin - by immune enzyme 
assay (ELISA) with kits from Diagnostic Systems 
Laboratories, Inc. (U.S.A.).  
 
Pathomorphological examination. All animals were 
autopsied. Location, number and size of mammary 
tumors and their metastases in lungs were checked. All 
tumors, as well as the tissues and organs with suspected 
tumor development were excised and fixed in 10% 
neutral formalin. After the routine histological 
processing the tissues were embedded into paraffin. 5-
7μm thin histological sections were stained with 
hematoxylin and eosin and examined microscopically. 
Tumors were classified according to International 
Agency for Research on Cancer recommendations [44]. 
 
 Statistics. Experimental results were statistically 
processed by the methods of variation statistics with the 
use of STATGRAPH statistic program kit. The 
significance of the discrepancies with age-matched 
controls was defined according to the Student t-
criterion, Fischer exact method, χ2, non-parametric 
Wilcoxon-Mann-Whitney and Friedman RM ANOVA 
on Ranks. Student-Newman-Keuls Method was used for 
all pair wise multiple comparisons. Coefficients of 
correlation were estimated by Spearman method [45]. 
Differences in tumor incidence were evaluated by the 
Mantel-Hansel log-rank test.  
 
Parameters of Gompertz model were estimated using 
maximum likelihood method, non-linear optimization 
procedure [46] and self-written code in 'Matlab'; 
confidence intervals for the parameters were obtained 
using the bootstrap method [47]. 
 
For experimental group Cox regression model [48] was 
used to estimate relative risk of death and tumor 
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